Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bladder Cancer, May 2018

Free Subscription


Abstracts

Retrieve all available abstracts of the following 113 articles:
HTML format


 

Single Articles

  1. PALOU J, Pisano F, Sylvester R, Joniau S, et al
    Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought.
    World J Urol. 2018 May 2. pii: 10.1007/s00345-018-2299.
    Abstract    

    Abstract available

  2. SHIMIZU T, Tomogane M, Miyashita M, Ukimura O, et al
    Low dose gemcitabine increases the cytotoxicity of human Vgamma9Vdelta2 T cells in bladder cancer cells in vitro and in an orthotopic xenograft model.
    Oncoimmunology. 2018;7:e1424671.
    Abstract    

    Abstract available

  3. NAGAYA T, Okuyama S, Ogata F, Maruoka Y, et al
    Near infrared photoimmunotherapy targeting bladder cancer with a canine anti-epidermal growth factor receptor (EGFR) antibody.
    Oncotarget. 2018;9:19026-19038.
    Abstract    

    Abstract available

  4. IDE H, Inoue S, Mizushima T, Jiang G, et al
    Androgen Receptor Signaling Reduces Radiosensitivity in Bladder Cancer.
    Mol Cancer Ther. 2018 May 2. pii: 1535-7163.MCT-17-1061.
    Abstract    

    Abstract available

  5. TANG G, Zhen Y, Xie W, Wang Y, et al
    Preoperative hemoglobin-platelet ratio can significantly predict progression and mortality outcomes in patients with T1G3 bladder cancer undergoing transurethral resection of bladder tumor.
    Oncotarget. 2018;9:18627-18636.
    Abstract    

    Abstract available

  6. LU M, Liu X
    Comparison of GreenLight Laser Photoselective Vaporization and Thulium Laser Enucleation for Nonmuscle Invasive Bladder Cancer.
    Photomed Laser Surg. 2018 May 2. doi: 10.1089/pho.2018.4440.
    Abstract    

    Abstract available

  7. KIM D, Lee MH, Koo MA, Kwon BJ, et al
    Suppression of T24 human bladder cancer cells by ROS from locally delivered hematoporphyrin-containing polyurethane films.
    Photochem Photobiol Sci. 2018 May 2. doi: 10.1039/c7pp00424.
    Abstract    

    Abstract available

  8. FUKUMOTO K, Kikuchi E, Mikami S, Hayakawa N, et al
    Clinical Role of Programmed Cell Death-1 Expression in Patients with Non-muscle-invasive Bladder Cancer Recurring After Initial Bacillus Calmette-Guerin Therapy.
    Ann Surg Oncol. 2018 May 1. pii: 10.1245/s10434-018-6498.
    Abstract    

    Abstract available

  9. BREAU RH, Lavallee LT, Cnossen S, Witiuk K, et al
    Tranexamic Acid versus Placebo to Prevent Blood Transfusion during Radical Cystectomy for Bladder Cancer (TACT): Study Protocol for a Randomized Controlled Trial.
    Trials. 2018;19:261.
    Abstract    

    Abstract available

  10. CHENG J, Chen J, Zhang X, Mei H, et al
    Overexpression of CRNDE promotes the progression of bladder cancer.
    Biomed Pharmacother. 2018;99:638-644.
    Abstract    

    Abstract available

  11. MAAS M, Walz S, Stuhler V, Aufderklamm S, et al
    Molecular markers in disease detection and follow-up of patients with non-muscle invasive bladder cancer.
    Expert Rev Mol Diagn. 2018 Apr 30. doi: 10.1080/14737159.2018.1469979.
    Abstract    

    Abstract available

  12. KOUTSIOUMPA M, Chen HW, O'Brien N, Koinis F, et al
    MKAD-21 suppresses the oncogenic activity of the miR-21/PPP2R2A/ERK molecular network in bladder cancer.
    Mol Cancer Ther. 2018 Apr 27. pii: 1535-7163.MCT-17-1049.
    Abstract    

    Abstract available

  13. KWAN ML, Garren B, Nielsen ME, Tang L, et al
    Lifestyle and nutritional modifiable factors in the prevention and treatment of bladder cancer.
    Urol Oncol. 2018 Apr 24. pii: S1078-1439(18)30115.
    Abstract    

    Abstract available

  14. LOJK J, Bregar VB, Strojan K, Hudoklin S, et al
    Increased endocytosis of magnetic nanoparticles into cancerous urothelial cells versus normal urothelial cells.
    Histochem Cell Biol. 2018;149:45-59.
    Abstract    

    Abstract available

  15. ANDERSON B
    Bladder cancer: overview and disease management. Part 1: non-muscle-invasive bladder cancer.
    Br J Nurs. 2018;27:S27-S37.
    Abstract    

    Abstract available

  16. LI C, Wang Z, Feng N, Dong J, et al
    Human HLAF adjacent transcript 10 promotes the formation of cancer initiating cells and cisplatin resistance in bladder cancer.
    Mol Med Rep. 2018 May 9. doi: 10.3892/mmr.2018.9005.
    Abstract    

    Abstract available

  17. PAN P, Chen T, Zhang Y, Qi Z, et al
    LIN28A inhibits lysosomeassociated membrane glycoprotein 1 protein expression in embryonic stem and bladder cancer cells.
    Mol Med Rep. 2018 May 3. doi: 10.3892/mmr.2018.8965.
    Abstract    

    Abstract available

  18. WU CL, Ho JY, Hung SH, Yu DS, et al
    miR-429 expression in bladder cancer and its correlation with tumor behavior and clinical outcome.
    Kaohsiung J Med Sci. 2018;34:335-340.
    Abstract    

    Abstract available

  19. SHIN DW, Park HS, Lee SH, Jeon SH, et al
    Health-Related Quality of Life, Perceived Social Support, and Depression in Disease-Free Survivors Who Underwent Curative Surgery Only for Prostate, Kidney and Bladder cancer: Comparison among survivors and with the General Population.
    Cancer Res Treat. 2018 May 4. pii: crt.2018.053. doi: 10.4143/crt.2018.
    Abstract    

    Abstract available

  20. CHANTADA-ABAL V, Chantada-Tirado C, Lamas-Diaz L, Carames-Masana F, et al
    [Sequential treatment with Mitomycin C and BCG in non muscle invasive bladder cancer.]
    Arch Esp Urol. 2018;71:453-457.
    Abstract    

    Abstract available

  21. AMINSHARIFI A, Brousell SC, Chang A, Leon J, et al
    Heat-targeted drug delivery: A promising approach for organsparing treatment of bladder cancer.THERMODOX(R).
    Arch Esp Urol. 2018;71:447-452.
    Abstract    

    Abstract available

  22. LEON-MATA J, Dominguez JL, Redorta JP, Sousa Gonzalez D, et al
    Analysis of tolerance and security of chemo hyperthermia with Mitomycin C for the treatment of non-muscle invasive bladder cancer.
    Arch Esp Urol. 2018;71:426-437.
    Abstract    

    Abstract available

  23. COENEN JJMJH, van Valenberg FJP, Arends TJH, Witjes JA, et al
    [Chemohyperthermia using MMC in non-muscle-invasive bladder cancer: Current status and future perspectives.]
    Arch Esp Urol. 2018;71:400-408.
    Abstract    

    Abstract available

  24. SANCHEZ GONZALEZ A, Rodriguez Faba O, Mosquera L, Sabiote L, et al
    [BCG and bladder cancer: Past, present and future.]
    Arch Esp Urol. 2018;71:332-341.
    Abstract    

    Abstract available

  25. SOUSA ESCANDON A
    Something is changing in the diagnosis and treatment of non-muscle invasive bladder cancers (NMIBC).
    Arch Esp Urol. 2018;71:325-327.
    Abstract    



  26. CAO Y, He Y, Chen H, He S, et al
    Phase I study of gemcitabine-cisplatin versus pemetrexed cisplatin for patients with advanced or metastatic bladder cancer.
    J BUON. 2018;23:475-481.
    Abstract    

    Abstract available

  27. LENFANT L, Verhoest G, Campi R, Parra J, et al
    Perioperative outcomes and complications of intracorporeal vs extracorporeal urinary diversion after robot-assisted radical cystectomy for bladder cancer: a real-life, multi-institutional french study.
    World J Urol. 2018 May 9. pii: 10.1007/s00345-018-2313.
    Abstract    

    Abstract available

  28. ZAAK D, Ohlmann C, Stenzl A
    [Current and established diagnostic modalities for bladder cancer].
    Urologe A. 2018 May 9. pii: 10.1007/s00120-018-0650.
    Abstract    

    Abstract available

  29. YOSHIDA T, Singh AK, Bishai WR, McConkey DJ, et al
    Organoid culture of bladder cancer cells.
    Investig Clin Urol. 2018;59:149-151.
    Abstract    



  30. NAKANO M, Omae K, Takebayashi T, Tanaka S, et al
    An epidemic of bladder cancer: ten cases of bladder cancer in male Japanese workers exposed to ortho-toluidine.
    J Occup Health. 2018 May 9. doi: 10.1539/joh.2017-0220.
    Abstract    

    Abstract available

  31. ZHANG Y, Fang L, Zang Y, Xu Z, et al
    Identification of Core Genes and Key Pathways via Integrated Analysis of Gene Expression and DNA Methylation Profiles in Bladder Cancer.
    Med Sci Monit. 2018;24:3024-3033.
    Abstract    

    Abstract available

  32. LUAN T, Zou R, Huang L, Li N, et al
    Hsa-miR-3658 Promotes Cell Proliferation, Migration and Invasion by Effecting LASS2 in Bladder Cancer.
    Clin Lab. 2018;64:515-525.
    Abstract    

    Abstract available

  33. D'ANDREA D, Hassler MR, Abufaraj M, Soria F, et al
    Progressive tissue biomarker profiling in non-muscle-invasive bladder cancer.
    Expert Rev Anticancer Ther. 2018 May 9:1-9. doi: 10.1080/14737140.2018.1474104.
    Abstract    

    Abstract available

  34. CHU HA, Crawford-Brown D
    Correction: Chu et al. Inorganic Arsenic in Drinking Water and Bladder Cancer: A Meta-Analysis for Dose-Response Assessment. Int. J. Environ. Res. Public Health 2006, 3(4), 316(-)322.
    Int J Environ Res Public Health. 2018;15.
    Abstract    



  35. FLANNERY K, Cao X, He J, Zhong Y, et al
    Survival Rates and Health Care Costs for Patients With Advanced Bladder Cancer Treated and Untreated With Chemotherapy.
    Clin Genitourin Cancer. 2018 Mar 27. pii: S1558-7673(18)30211.
    Abstract    

    Abstract available

  36. YOROZUYA W, Nishiyama N, Shindo T, Kyoda Y, et al
    Bacillus Calmette-Guerin may have clinical benefit for glandular or squamous differentiation in non-muscle invasive bladder cancer patients: retrospective multicenter study.
    Jpn J Clin Oncol. 2018 May 4. pii: 4992852. doi: 10.1093.
    Abstract    

    Abstract available

  37. KWEON TD, Lee KY
    Spinal anesthesia is associated with lower recurrence rates after resection of non-muscle invasive bladder cancer.
    Transl Androl Urol. 2018;7:283-286.
    Abstract    



  38. DREJER D, Jensen JB, Bryan RT
    Red patches during bladder cancer surveillance: to biopsy or not to biopsy?
    Transl Androl Urol. 2018;7:280-282.
    Abstract    



  39. DIMITROPOULOS K, Tzortzis V
    Could there be a relationship between type of anesthesia and oncological parameters after transurethral resection of bladder cancer?
    Transl Androl Urol. 2018;7:287-288.
    Abstract    



  40. CHRISTOPH F, Schostak M
    Age does not matter: the relevance of immediate instillation therapy with Mitomycin C in non-muscle invasive bladder cancer.
    Transl Androl Urol. 2018;7:289-291.
    Abstract    



  41. MESSING EM
    Psychological Stress and Suicide in Bladder Cancer Patients.
    Bladder Cancer. 2018;4:245-246.
    Abstract    



  42. GALSKY MD, Pal SK, Lin SW, Ogale S, et al
    Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States.
    Bladder Cancer. 2018;4:227-238.
    Abstract    

    Abstract available

  43. DE MATURANA EL, Rava M, Anumudu C, Saez O, et al
    Bladder Cancer Genetic Susceptibility. A Systematic Review.
    Bladder Cancer. 2018;4:215-226.
    Abstract    

    Abstract available

  44. LEWIS GD, Haque W, Verma V, Butler EB, et al
    The Role of Adjuvant Radiation Therapy in Locally Advanced Bladder Cancer.
    Bladder Cancer. 2018;4:205-213.
    Abstract    

    Abstract available

  45. KAISER J, Li H, North SA, Leibowitz-Amit R, et al
    The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study.
    Bladder Cancer. 2018;4:185-194.
    Abstract    

    Abstract available

  46. ZUIVERLOON TCM, de Jong FC, Costello JC, Theodorescu D, et al
    Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell Lines.
    Bladder Cancer. 2018;4:169-183.
    Abstract    

    Abstract available

  47. ZAREBA P, Duivenvoorden WCM, Pinthus JH
    Thromboembolism in Patients with Bladder Cancer: Incidence, Risk Factors and Prevention.
    Bladder Cancer. 2018;4:139-147.
    Abstract    

    Abstract available

  48. AL JOHI RS, Seifeldein GS, Moeen AM, Aboulhagag NA, et al
    Diffusion weighted magnetic resonance imaging in bladder cancer, is it time to replace biopsy?
    Cent European J Urol. 2018;71:31-37.
    Abstract    

    Abstract available

  49. AKITAKE M, Kiyoshima K, Yokomizo A, Shiga K, et al
    A rational risk assessment for intravesical recurrence in primary low-grade Ta bladder cancer: A retrospective analysis of 245 cases.
    Mol Clin Oncol. 2018;8:785-790.
    Abstract    

    Abstract available

  50. HORI S, Miyake M, Tatsumi Y, Morizawa Y, et al
    Gamma-Klotho exhibits multiple roles in tumor growth of human bladder cancer.
    Oncotarget. 2018;9:19508-19524.
    Abstract    

    Abstract available

  51. GAI JW, Wahafu W, Song L, Ping H, et al
    Expression of CD74 in bladder cancer and its suppression in association with cancer proliferation, invasion and angiogenesis in HT-1376 cells.
    Oncol Lett. 2018;15:7631-7638.
    Abstract    

    Abstract available

  52. SATHIANATHEN NJ, Fan Y, Jarosek SL, Lawrentschuk NL, et al
    Finasteride does not prevent bladder cancer: A secondary analysis of the Medical Therapy for Prostatic Symptoms Study.
    Urol Oncol. 2018 May 3. pii: S1078-1439(18)30116.
    Abstract    

    Abstract available

  53. CRIJNEN J, de Reijke TM
    Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer.
    Expert Opin Emerg Drugs. 2018 May 5. doi: 10.1080/14728214.2018.1474201.
    Abstract    

    Abstract available

  54. DING XL, Yang DL, Yan RP, Li ZP, et al
    [Value of European Organisation for Research and Treatment of Cancer score system for predication of immediate postoperative intravesical instillation of pirarubicin after transurethral resection of non-muscle invasive bladder cancer].
    Zhonghua Zhong Liu Za Zhi. 2018;40:308-312.
    Abstract    

    Abstract available

  55. OTSUKA M, Taguchi S, Nakagawa T, Morikawa T, et al
    Clinical significance of random bladder biopsy in primary T1 bladder cancer.
    Mol Clin Oncol. 2018;8:665-670.
    Abstract    

    Abstract available

  56. YANG Y, Xu J, Zhang Q
    Detection of urinary survivin using a magnetic particles-based chemiluminescence immunoassay for the preliminary diagnosis of bladder cancer and renal cell carcinoma combined with LAPTM4B.
    Oncol Lett. 2018;15:7923-7933.
    Abstract    

    Abstract available

  57. CHEN D, Chen J, Guo Y, Li Y, et al
    Cinobufacini promotes apoptosis of bladder cancer cells by influencing the expression of autophagy-related genes.
    Oncol Lett. 2018;15:7104-7110.
    Abstract    

    Abstract available

  58. ZHENG Z, Zhu D, Zhao F, Han J, et al
    Upregulated GAPLINC predicts a poor prognosis in bladder cancer patients and promotes tumor proliferation and invasion.
    Oncol Lett. 2018;15:6770-6776.
    Abstract    

    Abstract available

  59. CHEN JF, Yu BX, Ma L, Lv XY, et al
    RON is overexpressed in bladder cancer and contributes to tumorigenic phenotypes in 5637 cells.
    Oncol Lett. 2018;15:6547-6554.
    Abstract    

    Abstract available

  60. KYRITSI F, Loffredo CA, Zheng YL, Philips G, et al
    Urinary Bladder Cancer in Egypt: Are There Gender Differences in Its Histopathological Presentation?
    Adv Urol. 2018;2018:3453808.
    Abstract    

    Abstract available

  61. LIN W, Xie J, Xu N, Huang L, et al
    Glaucocalyxin A induces G2/M cell cycle arrest and apoptosis through the PI3K/Akt pathway in human bladder cancer cells.
    Int J Biol Sci. 2018;14:418-426.
    Abstract    

    Abstract available

  62. DONG L, Lin F, Wu W, Liu Y, et al
    Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway.
    Int J Med Sci. 2018;15:645-652.
    Abstract    

    Abstract available

  63. VAN DER POL CB, Sahni VA, Eberhardt SC, Oto A, et al
    ACR Appropriateness Criteria((R)) Pretreatment Staging of Muscle-Invasive Bladder Cancer.
    J Am Coll Radiol. 2018;15.
    Abstract    

    Abstract available

  64. OUZAID I, Xylinas E
    Prevention of IVR: a need for investigation.
    Jpn J Clin Oncol. 2018;48:295-296.
    Abstract    

    Abstract available

  65. FANG CY, Chen JS, Chang SK, Shen CH, et al
    Reversine induces autophagic cell death through the AMP-activated protein kinase pathway in urothelial carcinoma cells.
    Anticancer Drugs. 2018;29:29-39.
    Abstract    

    Abstract available

  66. FUESSEL S, Lohse-Fischer A, Vu Van D, Salomo K, et al
    Quantification of MicroRNAs in Urine-Derived Specimens.
    Methods Mol Biol. 2018;1655:201-226.
    Abstract    

    Abstract available

  67. YOSHIDA T, Okuyama H, Endo H, Inoue M, et al
    Spheroid Cultures of Primary Urothelial Cancer Cells: Cancer Tissue-Originated Spheroid (CTOS) Method.
    Methods Mol Biol. 2018;1655:145-153.
    Abstract    

    Abstract available

  68. WHONGSIRI P, Phoyen S, Boonla C
    Oxidative Stress in Urothelial Carcinogenesis: Measurements of Protein Carbonylation and Intracellular Production of Reactive Oxygen Species.
    Methods Mol Biol. 2018;1655:109-117.
    Abstract    

    Abstract available

  69. JAGUVA VASUDEVAN AA, Goering W, Haussinger D, Munk C, et al
    Detection of APOBEC3 Proteins and Catalytic Activity in Urothelial Carcinoma.
    Methods Mol Biol. 2018;1655:97-107.
    Abstract    

    Abstract available

  70. MBANEFO EC, Hsieh MH
    Defining the Pathways of Urogenital Schistosomiasis-Associated Urothelial Carcinogenesis through Transgenic and Bladder Wall Egg Injection Models.
    Methods Mol Biol. 2018;1655:67-76.
    Abstract    

    Abstract available

  71. SJODAHL G
    Molecular Subtype Profiling of Urothelial Carcinoma Using a Subtype-Specific Immunohistochemistry Panel.
    Methods Mol Biol. 2018;1655:53-64.
    Abstract    

    Abstract available

  72. ALAMYAR M, Zwarthoff EC
    Analysis of Point Mutations in Clinical Samples of Urothelial Carcinoma.
    Methods Mol Biol. 2018;1655:19-28.
    Abstract    

    Abstract available

  73. LI R, Petros FG, Davis JW
    Extended Pelvic Lymph Node Dissection in Bladder Cancer.
    J Endourol. 2018;32.
    Abstract    

    Abstract available

  74. WOOLBRIGHT BL, Ayres M, Taylor JA 3rd
    Metabolic changes in bladder cancer.
    Urol Oncol. 2018 May 14. pii: S1078-1439(18)30132.
    Abstract    

    Abstract available

  75. ZHU X, Li Y, Zhao S, Zhao S, et al
    LSINCT5 activates Wnt/beta-catenin signaling by interacting with NCYM to promote bladder cancer progression.
    Biochem Biophys Res Commun. 2018 May 14. pii: S0006-291X(18)31133.
    Abstract    

    Abstract available

  76. TRAN-HARDING K, Nair RT, Ganesh H
    Renal Granulomatosis Post Intravesical Bacillus Calmette-Guerin Therapy for Non-muscle-invasive Bladder Cancer.
    J Clin Imaging Sci. 2018;8:18.
    Abstract    

    Abstract available

  77. FALKE J, Hulsbergen-van de Kaa CA, Maj R, Oosterwijk E, et al
    A placebo-controlled efficacy study of the intravesical immunomodulators TMX-101 and TMX-202 in an orthotopic bladder cancer rat model.
    World J Urol. 2018 May 16. pii: 10.1007/s00345-018-2334.
    Abstract    

    Abstract available

  78. GE P, Wang L, Lu M, Mao L, et al
    Oncological Outcome of Primary and Secondary Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Sci Rep. 2018;8:7543.
    Abstract    

    Abstract available

  79. LAM TBL
    Optimizing the diagnosis of pelvic lymph node metastasis in bladder cancer using computed tomography and magnetic resonance imaging.
    Cancer Commun (Lond). 2018;38:2.
    Abstract    



  80. GOONEWARDENA SAS, Jayarajah U, Kuruppu SN, Herath HMKB, et al
    Clinical outcomes in a cohort of patients with T1 high grade urothelial bladder cancer not receiving intravesical bacillus Calmette-Guerin: a 15 year experience
    Ceylon Med J. 2018;63:37-39.
    Abstract    



  81. BABA M, Kageyama S, Yoshida T, Fujiwara R, et al
    Intravesical bacillus Calmette-Guerin therapy after second transurethral resection for primary T1 bladder cancer.
    Int J Clin Oncol. 2018 May 14. pii: 10.1007/s10147-018-1292.
    Abstract    

    Abstract available

  82. MARTIN JW, Vernez SL, Lotan Y, Abdelhalim A, et al
    Pathological characteristics and prognostic indicators of different histopathological types of urinary bladder cancer following radical cystectomy in a large single-center Egyptian cohort.
    World J Urol. 2018 May 14. pii: 10.1007/s00345-018-2331.
    Abstract    

    Abstract available

  83. XU W, Xia H, Liu W, Zheng W, et al
    Exploration of genetics commonness between bladder cancer and breast cancer based on a silcio analysis on disease subtypes.
    Technol Health Care. 2018 Apr 27. pii: THC174699. doi: 10.3233/THC-174699.
    Abstract    

    Abstract available

  84. PARDINI B, Cordero F, Naccarati A, Viberti C, et al
    microRNA profiles in urine by next-generation sequencing can stratify bladder cancer subtypes.
    Oncotarget. 2018;9:20658-20669.
    Abstract    

    Abstract available

  85. LEVI L, Groh M, De Castro N, Bergeron A, et al
    [BCG infection following intravesicular immunotherapy for bladder cancer].
    Rev Mal Respir. 2018 May 10. pii: S0761-8425(18)30073.
    Abstract    

    Abstract available

  86. WANG Y, Hu D, Yu H, Shen Y, et al
    Comparison of the Diagnostic Value of Monoexponential, Biexponential, and Stretched Exponential Diffusion-weighted MRI in Differentiating Tumor Stage and Histological Grade of Bladder Cancer.
    Acad Radiol. 2018 May 9. pii: S1076-6332(18)30199.
    Abstract    

    Abstract available

  87. LIU XP, Yin XH, Yan XH, Zeng XT, et al
    The Clinical Relevance of Fragile Histidine Triad Protein (FHIT) in Patients with Bladder Cancer.
    Med Sci Monit. 2018;24:3113-3118.
    Abstract    

    Abstract available

  88. JIN CY, Molagoda IMN, Karunarathne WAHM, Kang SH, et al
    TRAIL attenuates sulforaphane-mediated Nrf2 and sustains ROS generation, leading to apoptosis of TRAIL-resistant human bladder cancer cells.
    Toxicol Appl Pharmacol. 2018 May 21. pii: S0041-008X(18)30233.
    Abstract    

    Abstract available

  89. WEBER C
    A biobank for bladder cancer.
    Nat Cell Biol. 2018 May 21. pii: 10.1038/s41556-018-0114.
    Abstract    



  90. YUEN JWM, Mak DSY, Chan ES, Gohel MDI, et al
    Tumor inhibitory effects of intravesical Ganoderma lucidum instillation in the syngeneic orthotopic MB49/C57 bladder cancer mice model.
    J Ethnopharmacol. 2018 May 18. pii: S0378-8741(18)31199.
    Abstract    

    Abstract available

  91. MICHELS CTJ, Wijburg CJ, Leijte E, Witjes JA, et al
    A cost-effectiveness modeling study of robot-assisted (RARC) versus open radical cystectomy (ORC) for bladder cancer to inform future research.
    Eur Urol Focus. 2018 May 18. pii: S2405-4569(18)30104.
    Abstract    

    Abstract available

  92. BILSEN MP, van Meijgaarden KE, de Jong HK, Joosten SA, et al
    A novel view on the pathogenesis of complications after intravesical BCG for bladder cancer.
    Int J Infect Dis. 2018 May 17. pii: S1201-9712(18)34414.
    Abstract    

    Abstract available

  93. KAYAMA E, Kikuchi E, Fukumoto K, Shirotake S, et al
    History of Non-Muscle-Invasive Bladder Cancer May Have a Worse Prognostic Impact in cT2-4aN0M0 Bladder Cancer Patients Treated With Radical Cystectomy.
    Clin Genitourin Cancer. 2018 Apr 28. pii: S1558-7673(18)30303.
    Abstract    

    Abstract available

  94. BENNETT MH, Feldmeier J, Smee R, Milross C, et al
    Hyperbaric oxygenation for tumour sensitisation to radiotherapy.
    Cochrane Database Syst Rev. 2018;4:CD005007.
    Abstract    

    Abstract available

  95. VALLEJO-BENITEZ A, Rodriguez-Zarco E, Pabon-Carrasco S, Espinal PS, et al
    [Small cell bladder carcinoma in age extremes: Report of two cases.]
    Arch Esp Urol. 2018;71:204-207.
    Abstract    

    Abstract available

  96. TURAN T, Efiloglu O, Gunaydin B, Ozkanli S, et al
    Comparative differences between T1a/b and T1e/m as substages in T1 urothelial carcinoma of the bladder.
    Int Braz J Urol. 2018;44:267-272.
    Abstract    

    Abstract available

  97. TANG S, Hao H, Fang D, Zheng W, et al
    Prostate cancer incidentally discovered at the time of radical cystoprostatectomy does not decrease overall survival: Results from a large Chinese medical center.
    Int Braz J Urol. 2018;44:258-266.
    Abstract    

    Abstract available

  98. REXIN P, Tauchert A, Hanze J, Heers H, et al
    The Immune Checkpoint Molecule CD200 Is Associated with Tumor Grading and Metastasis in Bladder Cancer.
    Anticancer Res. 2018;38:2749-2754.
    Abstract    

    Abstract available

  99. OWARI T, Miyake M, Nakai Y, Morizawa Y, et al
    A Genitourinary Cancer-specific Scoring System for the Prediction of Survival in Patients with Bone Metastasis: A Retrospective Analysis of Prostate Cancer, Renal Cell Carcinoma, and Urothelial Carcinoma.
    Anticancer Res. 2018;38:3097-3103.
    Abstract    

    Abstract available

  100. NA R, Wu Y, Jiang G, Yu H, et al
    Germline Mutations in DNA Repair Genes are Associated with Bladder Cancer Risk and Unfavorable Prognosis.
    BJU Int. 2018 May 4. doi: 10.1111/bju.14370.
    Abstract    

    Abstract available

  101. GANDHI N, Krishna S, Booth CM, Breau RH, et al
    Diagnostic accuracy of MRI for tumor staging of bladder cancer: Systematic review and Meta-Analysis.
    BJU Int. 2018 May 4. doi: 10.1111/bju.14366.
    Abstract    

    Abstract available

  102. MASON SJ, Catto JW, Downing A, Bottomley SE, et al
    Evaluating Patient Reported Outcome Measures (PROMs) for bladder cancer: a systematic review using the COSMIN checklist.
    BJU Int. 2018 May 3. doi: 10.1111/bju.14368.
    Abstract    

    Abstract available

  103. MASON SJ, Downing A, Wright P, Hounsome L, et al
    Health-related quality of life after treatment for bladder cancer in England.
    Br J Cancer. 2018 May 14. pii: 10.1038/s41416-018-0084.
    Abstract    

    Abstract available

  104. SMITH AB, Chisolm S, Deal A, Spangler A, et al
    Patient-centered prioritization of bladder cancer research.
    Cancer. 2018 May 4. doi: 10.1002/cncr.31530.
    Abstract    

    Abstract available

  105. CHEN A, Fu G, Xu Z, Sun Y, et al
    Detection of Bladder Cancer Via Microfluidic Immunoassay and Single-Cell DNA Copy Number Alteration Analysis of Captured Urinary Exfoliated Tumor Cells.
    Cancer Res. 2018 May 22. pii: 0008-5472.CAN-17-2615.
    Abstract    

    Abstract available

  106. PANEBIANCO V, Narumi Y, Altun E, Bochner BH, et al
    Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System).
    Eur Urol. 2018 May 10. pii: S0302-2838(18)30335.
    Abstract    

    Abstract available

  107. TELEKA S, Haggstrom C, Nagel G, Bjorge T, et al
    Risk of bladder cancer by disease severity in relation to metabolic factors and smoking; a prospective pooled cohort study of 800,000 men and women.
    Int J Cancer. 2018 May 14. doi: 10.1002/ijc.31597.
    Abstract    

    Abstract available

  108. IYER G, Balar AV, Milowsky MI, Bochner BH, et al
    Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.
    J Clin Oncol. 2018 May 9:JCO2017750158. doi: 10.1200/JCO.2017.75.0158.
    Abstract    

    Abstract available

  109. MAKELA VJ, Kotsar A, Tammela TL, Murtola TJ, et al
    Bladder cancer survival in men using 5-alpha-reductase inhibitors.
    J Urol. 2018 May 3. pii: S0022-5347(18)43085-6. doi: 10.1016/j.juro.2018.
    Abstract    

    Abstract available

  110. MAZZA P, Moran GW, Li G, Robins DJ, et al
    Conservative Management Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Contemporary Outcomes of a Multi-Institutional Cohort Study.
    J Urol. 2018 May 19. pii: S0022-5347(18)43234-X. doi: 10.1016/j.juro.2018.
    Abstract    

    Abstract available

  111. LI WL, Yu HY, Zhang XJ, Ke M, et al
    Purple sweet potato anthocyanin exerts antitumor effect in bladder cancer.
    Oncol Rep. 2018 May 8. doi: 10.3892/or.2018.6421.
    Abstract    

    Abstract available

  112. DRAEGER DL, Sievert KD, Hakenberg OW
    Psychosocial Distress in Bladder Cancer Stratified by Gender, Age, Treatment, and Tumour Stage.
    Urol Int. 2018 May 14:1-7. doi: 10.1159/000489502.
    Abstract    

    Abstract available

  113. TAPIERO S, Helfand A, Kedar D, Yossepowitch O, et al
    Patient Compliance with Maintenance Intravesical Therapy for Non-Muscle Invasive Bladder Cancer.
    Urology. 2018 May 21. pii: S0090-4295(18)30473.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;